IVD Reagent Lot Traceability: From Kit Label to Production History
IVD labeling requirements include a lot or control number traceable to production history. A readiness review should test the connection between the actual label and the underlying records.
Begin with the marketed configuration
FDA’s IVD labeling page describes the lot or control-number requirements in 21 CFR 809.10. It also addresses traceability for individual units in multiple-unit products, instrument subassemblies, and suitable uniform identification for components used together as a system. The details should be applied to the specific product and applicable labeling provisions.
For an internal exercise, start with a released kit rather than a blank label template. Record which components, label versions, and instructions belong to that configuration. This helps prevent a review from stopping at an identifier that is printed correctly but cannot be followed into the records.
Build a practical trace
- Start with the kit or reagent identifier on the actual distributed label.
- Locate the associated production and release records.
- Follow relevant components to their recorded lots and dispositions.
- Confirm the labeling and instructions that accompanied the configuration.
- Check how distribution information and a later complaint would connect to the same product.
Keep requirements and the audit exercise distinct
The labeling requirement and the applicable quality-system requirements are the regulatory basis. The trace above is a suggested way to examine whether the records work together. It is not a claim that FDA requires one universal traceability spreadsheet or a fixed retrieval time.
QMSR became effective on February 2, 2026. Use the current Part 820 framework and the requirements applicable to the device. Avoid treating a reference to the former quality-system regulation as a complete current compliance assessment.
Review changes and exceptions
If components are relabeled, replaced, combined into different kits, or supplied through another facility, identify how the records preserve the relevant relationship. Do not assume that matching product names establishes lot equivalence. Where an exception or alternate identification approach applies, retain the rationale and the relevant source.
A focused readiness review should surface gaps before a complaint, investigation, or correction requires the same trace. It does not establish that every product or process has been assessed.
Related inspection resources
Primary sources
Sources reviewed October 20, 2026. The preparation steps above are practical suggestions; the linked regulations and FDA documents define the applicable requirements.